Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples

American Journal of Clinical Pathology

Volumn 123, Issue 1, 2005, Pages 66-74

  Cruz, Ignacio ^b   Ciudad, Juana ^a   Cruz, Juan Jesús ^b   Ramos, Manuel ^b   Gómez Alonso, Alberto ^b   Adansa, Juan Carlos ^b   Rodríguez, Cesar ^b   Orfao, Alberto ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Breast cancer; Cytokeratin; DNA ploidy; Flow cytometry; Minimal disease

Indexed keywords

CELL DNA; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN ANTIBODY; MONOCLONAL ANTIBODY; REAGENT;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL; CANCER CYTODIAGNOSIS; CELL LEVEL; CELL STRAIN MCF 7; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DILUTION; EPITHELIUM CELL; EVALUATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TECHNIQUE;

EID: 11244354345     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WP3QWKVJFYDHHXQD     Document Type: Article

References (55)

1. Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumor dissemination in breast cancer. Clin Cancer Res. 2003;15:6326-6334.
2. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-533.
3. Chabannon C, Olivero S, Viret F, et al. Detection of epithelial cells in hematopoietic organs of patients with breast cancer: physiopathological significance and clinical consequences. Acta Haematol. 2001;105:166-171.
4. Kell MR, Winter DC, O'Sullivan GC, et al. Biological behaviour and clinical implications of micrometastases. Br J Surg. 2000;87:1629-1639.
5. Baker M, Gillanders WE, Mikhitarian K, et al. The molecular detection of micrometastatic breast cancer. Am J Surg. 2003;186:351-358.
6. Corradini P, Voena C, Astolfi M, et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol. 2001;12:1693-1698.
7. Wasserman L, Dreilinger A, Easter D, et al. A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn. 1999;4:21-28.
8. Stathopoulou A, Mavroudis D, Perraki M, et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003;23:1883-1890.
9. Hawes D, Neville AM, Cote RJ. Detection of occult metastasis in patients with breast cancer. Semin Surg Oncol. 2001;20:312-318.
10. Jakub JW, Diaz NM, Ebert MD, et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg. 2002;184:302-306.
11. Hitchcock CL, Sampsel J, Young DC, et al. Limitations with light microscopy in the detection of colorectal cancer cells. Dis Colon Rectum. 1999;42:1046-1052.
12. Osborne MP, Wong GY, Asina S, et al. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res. 1991;51:2706-2709.
13. Osborne MP, Asina S, Wong GY. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. Cancer Res. 1989;49:2510-2513.
14. Ellis G, Ferguson M, Yamanaka E, et al. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer. 1989;63:2509-2514.
15. Cabioglu N, Igci A, Yildirim EO, et al. An ultrasensitive tumor enriched flow-cytometric assay for detection of isolated tumor cells in bone marrow of patients with breast cancer. Am J Surg. 2002;184:414-417.
16. Bischoff J, Rosenberg R, Dahm M, et al. Minimal residual disease in bone marrow and peripheral blood of patients with metastatic breast cancer. Recent Results Cancer Res. 2003;162:135440.
17. Kasimir-Bauer S, Oberhoff C, Sliwinska K, et al. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use? Breast Cancer Res Treat. 2001;69:123-132.
18. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet. 1988;4:277-281.
19. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
20. Goddard MJ, Wilson B, Grant JW. Comparison of commercially available cytokeratin antibodies in normal and neoplastic adult epithelial and non-epithelial tissues. J Clin Pathol. 1991;44:660-663.
21. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol. 1995;48:26-32.
22. Angus B, Purvis J, Stock D, et al. NCL-5D3: a new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue. J Pathol. 1987;153:377-384.
23. Jing Y, Zhang J, Waxman S, et al. Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation. 1996;60:109-117.
24. Prasad AR, Divine G, Zarbo RJ. Two-color, cytokeratin-labeled DNA flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. Arch Pathol Lab Med. 2001;125:364-374.
25. Kang HS, Youn YK, Oh SK, et al. Flow cytometric analysis of primary tumors and their corresponding metastatic nodes in breast cancer. Breast Cancer Res Treat. 2000;63:81-87.
26. Utada Y, Yoshimoto M, Kasumi F, et al. Relationship between DNA ploidy and survival in breast cancer [in Japanese]. Gan To Kagaku Ryoho. 1998;25(suppl 3):431-435.
27. Visscher DW, Wykes S, Zarbo RJ, et al. Multiparametric evaluation of flow cytometric synthesis phase fraction determination in dual-labeled breast carcinomas. Anal Quant Cytol Histol. 1991;13:246-252.
28. Stomper PC, Budnick RM, Stewart CC. Use of specimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophenotyping in breast cancer. Cytometry. 2000;42:165-173.
29. Leers M, Schoffelen R, Hoop J, et al. Multiparameter flow cytometry as a tool for the detection of micrometastatic tumor cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol. 2002;55:359-366.
30. Leslie DS, Johnston WW, Daly L, et al. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol. 1990;94:8-13.
31. Beitsch PD, Clifford E. Detection of carcinoma cells in the blood of breast cancer patients. Am J Surg. 2000;180:446-449.
32. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983;3:323-327.
33. Maillo A, Diaz P, Blanco A, et al. Proportion of S-phase tumor cells measured by flow cytometry is an independent prognostic factor in meningioma tumors. Cytometry. 1999;38:118-123.
34. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol. 1998;16:3774-3781.
35. Orfao A, Garcia-Sanz R, Lopez-Berges MC, et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry. 1994;17:332-339.
36. Wong LS, Bateman WJ, Morris AG, et al. Detection of circulating tumor cells with the magnetic activated cell sorter. Br J Surg. 1995;82:1333-1337.
37. -7. Proc Natl Acad Sci U S A. 1995;92:537-541.
38. Simpson SJ, Vachula M, Kennedy MJ, et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol. 1995;23:1062-1068.
39. Vredenburgh JJ, Silva O, Tyer C, et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother. 1996;5:57-62.
40. Clevenger CV, Khandewal M, Stadtmauer E, et al. Detection of bone marrow breast carcinoma metastasis using multiparameter flow cytometry. Ann N Y Acad Sci. 1993;677:400-401.
41. Zoli W, Barzanti F, Dal Susino M, et al. Flow-cytometric determination of tumor cells in lymph nodes. Oncology. 2002;62:128-135.
42. Martin VM, Siewert C, Scharl A, et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACs. Exp Hematol. 1998;26:252-264.
43. Ghossein RA, Carusone L, Bhattacharya S. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas. In Vivo. 2000;14:237-250.
44. - Molino A, Colombatti M, Bonetti F, et al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer. 1991;67:1033-1036.
45. Shankey TV. Antibodies to intermediate filament proteins as probes for multiparameter flow cytometry of human cancers. In: Bauer D, ed. Clinical Flow Cytometry: Principles and Applications. Baltimore, MD: Williams & Wilkins; 1992:209-229.
46. Kirjushkina MS, Tchipysheva TA, Ermilova VD, et al. Breast tumor diagnosis in cytologic aspirates using monoclonal antibodies to keratin 8 and 17. Acta Cytol 1997;41:307-312.
47. Oberhoff C, Kasimir-Bauer S, Wirth I, et al. Detection of isolated tumor cells in the bone marrow of patients with primary breast cancer using immunomagnetic separation and immunocytochemistry [abstract]. Proc ASCO. 1999;18:122. Abstract 462.
48. Wetzels RHW, Kuijpers HJH, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol. 1991;138:751-763.
49. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst. 1988;80:691-695.
50. Ferrero M, Spyratos F, Le Doussal V, et al. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry. 1990;11:716-724.
51. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19:276-289.
52. Tsubura A, Okada H, Senzaki H, et al. Keratin expression in the normal breast and in breast carcinoma. Histopathology. 1991;18:517-522.
53. Fang B, Zborowski M, Moore LR. Detection of rare MCF-7 breast carcinoma cells from mixtures of human peripheral leukocytes by magnetic deposition analysis. Cytometry. 1999;36:294-302.
54. Gross HJ, Verwer B, Houck D, et al. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry. 1993;14:519-526.
55. Schroder CP, Ruiters MH, de Jong S, et al. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer. 2003;106:611-618.